Beyond AI trading, a growth ace! Eli Lilly (LLY.US) expands the output of weight-loss drugs and introduces new products, with JPMorgan raising the target price to $1,650.

智通财经APP reports that JPMorgan is further raising its expectations for Eli Lilly (LLY.US) earnings growth in the coming years. The research team led by analyst Chris Schott reaffirmed Eli Lilly's "Overweight" rating and its position as the firm's "top pick," raising the December 2027 target price from $1,500 to $1,650. This represents an upside of approximately 20.1% compared to the closing price of $1,373.70 on October 29. The firm is optimistic not only about the current robust growth in weight-loss drug sales, but also about the long-term growth potential driven by overseas market expansion, rising obesity treatment penetration in the United States, and the launch of new oral products. As the AI capital expenditure cycle prompts the market to reassess the valuation and earnings performance of tech stocks, Eli Lilly is becoming another key growth focus on Wall Street.